Adaptive Biotechnologies Corp

For the period ended Jul 24, 2026. Filed Jul 29, 2026.

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Jul 24, 2026 · Filed Jul 29, 2026

Use the contents to explore the available documents and sections.

ADPT$27.98+4.3%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

EX-99.1 · Segment Information (Including Segment Adjusted EBITDA)

Segment Information (Including Segment Adjusted EBITDA)

The following sets forth segment information for the periods presented (in thousands, unaudited):

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
MRD:
Revenue	$66,168	$49,938	$133,261	$93,659
Adjusted EBITDA	9,116	1,912	21,254	(2,199)
Reconciliation of Net Income (Loss) to Adjusted EBITDA:
Net income (loss)	$382	$(7,180)	$3,744	$(19,418)
Depreciation and amortization expense	2,409	2,455	4,790	5,118
Impairment of long-lived assets	—	—	—	—
Restructuring expense	77	—	325	—
Share-based compensation expense	6,248	6,637	12,395	12,101
Adjusted EBITDA	$9,116	$1,912	$21,254	$(2,199)
Immune Medicine(1):
Revenue	$5,385	$8,941	$9,166	$17,663
Adjusted EBITDA	(6,269)	(5,721)	(16,629)	(10,827)
Reconciliation of Net Loss to Adjusted EBITDA:
Net loss	$(10,055)	$(11,770)	$(25,984)	$(22,689)
Depreciation and amortization expense	826	1,585	1,831	3,208
Impairment of long-lived assets	—	—	347	—
Restructuring expense	—	—	395	—
Share-based compensation expense	2,960	4,464	6,782	8,654
Adjusted EBITDA	$(6,269)	$(5,721)	$(16,629)	$(10,827)

(1)Expenses related to Digital Biotechnologies, Inc. are no longer included in the Immune Medicine segment.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.